Compare FBYD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBYD | AGEN |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.1M | 335.6M |
| IPO Year | 2023 | 1999 |
| Metric | FBYD | AGEN |
|---|---|---|
| Price | $8.26 | $6.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.33 |
| AVG Volume (30 Days) | 70.7K | ★ 1.0M |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 0.04 | ★ 0.96 |
| Revenue | $14,896,000.00 | ★ $42,877,086.00 |
| Revenue This Year | N/A | $9.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $208.50 | ★ $6.29 |
| Revenue Growth | ★ 120.85 | 89.95 |
| 52 Week Low | $3.71 | $2.71 |
| 52 Week High | $29.02 | $10.19 |
| Indicator | FBYD | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 35.80 |
| Support Level | $6.01 | $2.96 |
| Resistance Level | $8.65 | $8.64 |
| Average True Range (ATR) | 0.52 | 0.59 |
| MACD | 0.05 | -0.28 |
| Stochastic Oscillator | 22.45 | 4.18 |
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.